_quizartinib-for-flt3-itd-positive-aml-after-second-line-chemo-or-stem-cell-transplant.jpg "Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant from flt3 itd mutation positive Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 26 sec
✓ Published: 16-Jan-2018
✓ Published: 16-Jan-2018
Description:
Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukaemia (AML), whose leukaemia has the FLT3-ITD mutation.nnQuizartinib is the first and only single-agent drug that has produced a clinical benefit in AML patients with this deadly mutation who have failed previous therapy.nnThe number of patients bridged to a stem cell transplant was very significant. Dr Levis and his colleagues pl
Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukaemia (AML), whose leukaemia has the FLT3-ITD mutation.nnQuizartinib is the first and only single-agent drug that has produced a clinical benefit in AML patients with this deadly mutation who have failed previous therapy.nnThe number of patients bridged to a stem cell transplant was very significant. Dr Levis and his colleagues pl
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_quizartinib-improves-survival-in-patients-with-flt3-itd-mutated-r-r-aml-quantum-r-trial.webp "Presented by Mark J. Levis, MD, PhD nnDr. Levis presents results of the QuANTUM-R trial, the first positive phase 3 trial to demonstrate improved OS with single-agent quizartinib in the R/R FLT3-ITD AML setting compared with salvage chemotherapy. The data confirm the safety and efficacy of quizartinib and the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.")
⏲ 4 min 52 sec ✓ 23-Jul-2018
_what-is-flt3-positive-aml-what-is-gilteritinib-aml.webp "HealthTree University for Blood Cancers")
_best-treatment-strategy-for-flt3-itd-aml.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_significance-of-flt3-mutations-in-aml.webp "OncLiveTV")
_aml17-trial-update-flt3-itd-mutation-and-daunorubicin-dosage.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_quizartinib-advances-overall-survival-in-acute-myeloid-leukaemia-patients.webp "Dr Harry Erba speaks to ecancer at the EHA 2022 meeting about quizartinib improving the overall survival in adult patients with FLT3-ITD+ acutenmyeloid leukaemia.nn Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25% of all newly diagnosed cases carry the FLT3-internal tandem duplication (ITD) gene mutation.nnThe results showed that the addition of quizartinib significantly improved overall survival compared with standard induction and consolidation")
⏲ 2 min 14 sec ✓ 11-Jun-2022
_what-is-flt3-mutated-acute-myeloid-leukemia.webp "Patient Empowerment Network")
_quizartinib-improves-survival-in-patients-with-flt3-itd-mutated-r-r-aml-quantum-r-trial.jpg)
_what-is-flt3-positive-aml-what-is-gilteritinib-aml.jpg)
_best-treatment-strategy-for-flt3-itd-aml.jpg)
_significance-of-flt3-mutations-in-aml.jpg)
_aml17-trial-update-flt3-itd-mutation-and-daunorubicin-dosage.jpg)
_quizartinib-advances-overall-survival-in-acute-myeloid-leukaemia-patients.jpg)
_what-is-flt3-mutated-acute-myeloid-leukemia.jpg)
![[+]](/images/menu.gif){kind=small}